Frank Laukien
President & CEO @ Bruker
Hampton, United States
Frank Laukien is a seed investor at Bruker in Hampton focused on Biotechnology and Health Care. Frank H. Laukien is based out of Hampton, New Hampshire and is the President & CEO and Chairman of the Board of Directors of Bruker. Frank previously worked at ALDA, Analytical, Life Science and Diagnostic Association as the Chairman of the Board. Frank H. Laukien attended Harvard University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Frank Laukien invests in
Stages Frank Laukien invests in
Countries Frank Laukien invests in
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 2 (67%)
- Medical Device 2 (67%)
- Medical 1 (33%)
- Analytics 1 (33%)
Stage
- Seed 1 (33%)
- Series B 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- Germany 1 (33%)
- Switzerland 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Navignostics
|
Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $7.6M / Seed / Nov 09, 2022 | |
PrognomiQ
|
PrognomiQ is a biotechnology firm that develops test products for the early detection and treatment of cancer and other complex diseases through the power of multi-omics data. | $46M / Venture - Series Unknown / Mar 15, 2022 | |
PreOmics
|
PreOmics develops and provides innovative tools for customers around the world for mass spectrometry (MS)-based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry.They at PreOmics develop and provide innovative technologies for mass spectrometry-based proteomics to make your research simply better. Their mission is to provide you with the best possible solutions and at the highest quality to achieve your results faster, easier and in a more robust manner than ever before. | $15.3M / Series B / Jan 19, 2022 |
Co-Investors
About Bruker
Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.
Bruker Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Erez Sokolski
Project Manager
|
|||
|
Frank Laukien
President & CEO
|
|||
Hermann Requardt
Member of the Board of Directors
|
|||
Jason Faessler
Vice President, Financial Planning and Analysis
|
|||
Lance Kuhn
Director Of Customer Service
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Frank Laukien invest in?
Frank Laukien invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Frank Laukien last invest?
The most recent investment recorded for Frank Laukien closed in Nov 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
